Trials / Completed
CompletedNCT00616811
Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency
A Multi-center, Randomized, Double-blind, Active-controlled Clinical Trial to Evaluate the Safety and Tolerability of 24 Weeks Treatment With Vildagliptin (50 mg qd) Versus Sitagliptin (25 mg qd) in Patients With Type 2 Diabetes and Severe Renal Insufficiency
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 148 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This clinical trial is designed to provide additional information on the safety and tolerability of vildagliptin (50 mg once daily (qd)) and sitagliptin (25 mg qd) when used in patients with type 2 diabetes mellitus(T2DM) and severe renal insufficiency (Glomerular filtration rate (GFR) \< 30 mL/min) for a period of 24 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | vildagliptin | |
| DRUG | Sitagliptin |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2010-10-01
- Completion
- 2010-10-01
- First posted
- 2008-02-15
- Last updated
- 2020-12-17
Locations
79 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00616811. Inclusion in this directory is not an endorsement.